Application of the WHOQOL-100 for the assessment of quality of life of adult patients with inherited metabolic diseases

Molecular Genetics and Metabolism

Volumn 106, Issue 1, 2012, Pages 25-30

  Cazzorla, Chiara ^a   Del Rizzo, Monica ^a   Burgard, Peter ^b   Zanco, Chiara ^a   Bordugo, Andrea ^a   Burlina, Alberto B ^a   Burlina, Alessandro P ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adult patients; Dietary treatment; Fabry disease; Inherited metabolic diseases (IMD); Phenylketonuria; Quality of life

Indexed keywords

AMINO ACID; CARBOHYDRATE;

ACIDURIA; ADOLESCENT; ADULT; ARTICLE; CADASIL; CARBOHYDRATE METABOLISM; CLINICAL FEATURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIET THERAPY; FEMALE; GENETIC DISORDER; HUMAN; HUMAN RELATION; INTERVIEW; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PATIENT CARE; PATIENT COMPLIANCE; PHENYLKETONURIA; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SOCIAL BEHAVIOR; SOCIAL INTERACTION; UREA CYCLE DISORDER; WORLD HEALTH ORGANIZATION QUALITY OF LIFE QUESTIONNAIRE 100;

ADULT; DIET THERAPY; FEMALE; HUMANS; MALE; METABOLIC DISEASES; PATIENTS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84860157525     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.02.008     Document Type: Article

References (19)

1. Lee P.J. Growing older: the adult metabolic clinic. J. Inherit. Metab. Dis. 2002, 25:252-260.
2. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual. Life Outcomes 2008, 6:6-25.
3. Bik-Multanowski M., Didycz B., Mozrzymas R., Nowacka M., Kaluzny L., Cichy W., Schneiberg B., Amilkiewicz J., Bilar A., Gizewska M., Lange A., Starostecka E., Chrobot A., Wojcicka-Bartlomiejczyk B.I., Milanowski A. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J. Inherit. Metab. Dis. 2008, 31(Suppl 2):415-418.
4. Gassiò R., Campistol J., Vilaseca M.A., Lambruschini N., Cambra F.J., Fusté E. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of phenylalanine-restricted diet?. Acta Paediatr. 2003, 92:1474-1478.
5. Bosch A.M., Tybout W., van Spronsen F.J., de Valk H.W., Wijburg F.A., Grootenhuis M.A. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:29-34.
6. MacLaughlin E.J., Raehl C.L., Treadway A.K., Sterling T.L., Zoller D.P., Bond C.A. Assessing medication adherence in the elderly. Which tools to use in clinical practice?. Drugs Aging 2005, 22:231-255.
7. Vegni E., Fiori L., Riva E., Giovannini M., Moja E.A. How individuals with phenylketonuria experience their illness: an age-related qualitative study. Child Care Health Dev. 2010, 36:539-548.
8. Wechsler D. Wechsler Adult Intelligence Scale Revised (WAIS-R), Adattamento italiano a cura di Caterina Laicardi e Arturo Orsini 1997, O.S. Organizzazioni Speciali (Firenze).
9. Chabriat H., Joutel A., Dichgans M., Tournier-Lasserve E., Bousser M.G. CADASIL. Lancet Neurol. 2009, 8:643-653.
10. The WHOQOL Group The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc. Sci. Med. 1998, 46:1569-1585.
11. Bonomi A.E., Patrick D.L., Bushnell D.M., Martin M. Validation of the United States' version of the World Health Organization Quality of Life (WHOQOL) instrument. J. Clin. Epidemiol. 2000, 53:1-12.
12. Power M., Harper A. The World Health Organization Quality of Life Group: The World Health Organization WHOQOL-100: test of the universality of quality of life in 15 different cultural groups worldwide. Health Psychol. 1999, 5:495-505.
13. De Girolamo G., Becchi M.A., Coppa F.S., Scocco P. Salute e qualità di vita 2001, Centro Scientifico Editore.
14. Martìnez Y., Prado-Aguilar C.A., Rascòn-Pacheco R.A., Valdivia-Mrtinez J.J. Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study. BMC Heal. Serv. Res. 2008, 8:164.
15. Bosch A.M., Grootenhuis M.A., Bakker H.D., Heijmans H.S., Wijburg F.A., Last B.F. Living with classical galactosemia: health-related quality of life consequences. Pediatrics 2004, 113:423-428.
16. Watt T., Burlina A.P., Cazzorla C., Schönfeld D., Banikazemi M., Hopkin R.J., Martins A.M., Sims K., Beitner-Johnson D., O'Brien F., Feldt-Rasmussen U. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet. Med. 2010, 12:703-712.
17. Machtelt Bouwman G., Maurice-Stam H., Linthorst G.E., Hollak C.E.M., Wijburg F.A., Grootenhuis M.A. Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life. Mol. Genet. Metab. 2011, 104:308-313.
18. Wilcox W.R., Oliveira J.P., Hopkin R.J., Ortiz A., Banikazemi M., Feldt-Rasmussen U., et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol. Genet. Metab. 2008, 93:112-128.
19. Cohen J.S., Biesecker B.B. Quality of life in rare genetic conditions: a systematic review of the literature. Am. J. Med. Genet. A 2010, 152A:1136-1156.